GE HealthCare’s MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to calculate the absorbed dose of radionuclides using a Monte Carlo method.
With this clearance, Monte Carlo dosimetry through the dose planning method (DPM) will be available for use with MIM SurePlan MRT, MIM Software’s software for automating and standardizing dosimetry in theranostics.
MIM SurePlan MRT with the DPM aims to provide faster and more accurate Monte Carlo dose calculations within seconds through a central processing unit in healthcare organizations’ existing hardware, the company said.
The company will showcase the software at the upcoming European Association of Nuclear Medicine (EANM) meeting in Hamburg, Germany, October 19 to 23, as well as at the RSNA conference in November in Chicago.
